AC Immune (NASDAQ:ACIU) Receives Buy Rating from HC Wainwright

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $16.00 price target on the stock.

AC Immune Stock Up 4.7 %

Shares of NASDAQ ACIU opened at $1.88 on Thursday. The company has a 50 day moving average of $2.43 and a 200 day moving average of $2.88. AC Immune has a twelve month low of $1.77 and a twelve month high of $4.98. The firm has a market cap of $188.77 million, a P/E ratio of -4.09 and a beta of 1.49.

Hedge Funds Weigh In On AC Immune

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in AC Immune by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock worth $220,000 after purchasing an additional 3,499 shares during the period. Quinn Opportunity Partners LLC purchased a new stake in AC Immune during the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP bought a new stake in shares of AC Immune during the fourth quarter valued at approximately $36,000. Boothbay Fund Management LLC purchased a new position in shares of AC Immune in the fourth quarter worth $38,000. Finally, RPO LLC bought a new position in shares of AC Immune during the fourth quarter worth $51,000. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.